Brosmed Medical Co., Ltd. appears in FDA premarket records as the applicant for peripheral angioplasty balloon catheters reviewed under product code LIT and, for one scoring catheter, product code PNO. The supplied collection links one 510(k) record, K262590, decided Substantially Equivalent on November 2, 2026, and the numbered sources also document earlier Parafleet SC and Tri-Wedge submissions. The company's own ODM/OEM site describes it as a balloon dilatation catheter manufacturer and an ODM/OEM partner; that characterization is the publisher's, not an independent assessment. [1][2][3][4][7]

Documented Parafleet clearances

K262590 covers the Parafleet NC 014 and Parafleet NC 018 PTA Balloon Dilatation Catheters, filed July 27, 2026 and decided November 2, 2026 as Substantially Equivalent under a Traditional review. The FDA record lists product code LIT, regulation number 870.1250, device class 2, the Cardiovascular advisory committee, and a Summary statement. The applicant address in that record is in Dongguan, China. [1]

An earlier clearance, K243704, covers the Parafleet SC 014, SC 018 and SC 035 PTA Balloon Dilatation Catheters. The FDA notification page identifies the same classification name, Catheter, Angioplasty, Peripheral, Transluminal, and the same applicant. The February 27, 2025 FDA letter for K243704 is addressed to Crystal Lee as Registration and Clinical Medicine Department Manager at the Dongguan address. [2][4]

The stated intended use for the Parafleet SC devices is to dilate stenoses in the iliac, femoral, iliofemoral, popliteal, infrapopliteal and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae; the same labeling states the devices are also indicated for stent dilatation. That wording describes cleared labeling scope, not measured performance. [2]

Scoring catheter filing

K241478 covers the Tri-Wedge PTA Scoring Balloon Dilatation Catheter, classified as Catheters, Peripheral, Cutting/Scoring under 21 CFR 870.1250, Class II with special controls, product code PNO, Cardiovascular panel. The October 22, 2024 FDA letter names Brosmed Medical Co., Ltd. as applicant and lists Crystal Lee as Registration Affairs Senior Manager. The submission documents describe the common name as Percutaneous Transluminal Angioplasty (PTA) Scoring Catheter. [7]

Company statements and corporate context

BrosMed's own ODM/OEM website presents the company as an ODM/OEM partner and states that it is the largest manufacturer of balloon dilatation catheter in China; the site also lists balloon catheters, catheters, guide wires, active devices, accessories and raw materials among its pages. These are company-published claims. A March 3, 2025 BrosMed news item announced FDA 510(k) clearance for the Parafleet SC 014, SC 018 and SC 035 models and described them as intended for symptomatic peripheral artery disease. [3][6]

A Chinese-language prospectus draft for Guangdong Brosmed Medical Co., Ltd. describes the firm as engaged in vascular interventional devices with more than 50 product series across coronary, peripheral, neurovascular, dialysis access and accessory areas, and lists a proposed listing on the Shenzhen Stock Exchange ChiNext board. The draft states that the issuance application still required exchange and regulator procedures. It is a filing-stage document, not confirmation of a completed listing. [8]

How to read the filing record

The supplied collection contains one linked 510(k) record, K262590, with a Substantially Equivalent decision; the sample of one record carries the same single decision. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio size or safety performance. The numbered sources also include K243704 and K241478, which are not part of that linked collection. No recall records appear in the supplied sample. [1][2][4][7]